Galien week of innovation

Alexandra Moens is a PharmD who has been part of the clinical industry for over 6 years. Her aim is to make a positive impact on patient lives by working with innovative solutions, implementing enhanced clinical strategies and increasing diversity and equity in the drug development lifecycle.

Her scientific background and experience working with pharmaceutical partners hand-in-hand have positively impacted clinical teams to get new insights to successfully manage their portfolio strategy in the fast evolving clinical industry.

Product: red dot® V2 Clinical Analysis Software

Company: behold.ai

Therapeutic Area & Indication: AI algorithm technology to improve speed and sensitivity in detecting lung cancers.

About the Product:
Software as a medical device AI technology improves the speed and sensitivity of detecting lung cancer on a chest plain film by augmenting the performance of Radiologists to above expert reader levels. The autonomous rule out of normal chest x-rays adds extra AI radiological reporting capacity into the system in crisis. 

Product: BioDigit Home

Company: BioSensics

Therapeutic Area & Indication: Platform for collection of digital biomarkers of disease directly from patients at home.

About the Product:
BioDigit Home is a unified multi-modal platform for collection of digital biomarkers from patients in their home environment. BioDigit Home includes more than 100 digitized assessments of motor, speech and cognitive function. In addition, physical activity, posture, falls, gait, balance and motor symptoms (e.g., tremor) can be monitored continuously using wearable sensors and medical devices that are integrated in BioDigit Home. BioDigit Home provides unprecedented capabilities for measuring digital biomarkers in clinical trials and research. BioDigit Home has an immediate and appreciable impact on public health by expediting clinical trials and research in different diseases. In the longer term, BioDigit Home can be used to improve clinical care for a wide range of therapeutics areas, by providing a comprehensive remote monitoring solution to complement therapeutics in neurological diseases.

Research team:
Ashkan Vaziri
Daniel Schoonover

Product: IDx-DR

Company: Digital Diagnostics Inc.

Therapeutic Area & Indication: Autonomous AI system for diagnosis of diabetic retinopathy and diabetic macular edema.

About the Product:
Digital Diagnostics flagship product IDx-DR is a clinically aligned, artificial intelligence (AI) systems that fully automates the diagnosis of diabetic retinopathy (including macular edema), without requiring specialist overread. By enabling diagnostic assessments at the point-of-care, Digital Diagnostics aims to increase patient access to high-quality, affordable disease detection. Using IDx-DR, primary care providers are empowered to provide potentially vision saving diagnoses and treatment plans to patients who may never have been seen by a physician otherwise. IDx-DR bridges the gap between patients and eye care specialists while also helping primary care providers close care gaps and improve patient outcomes.

Research team:
Michael Abramoff, MD, PhD
Warren Clarida 

Product: Exscientia's end-to-end AI-driven precision medicine platform

Company: Exscientia

Therapeutic Area & Indication: End to end AI for simulated faster and more efficient approaches to discovery, design and development of human drugs.

About the Product:
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. The precision medicine platform enables a “patient-first” approach by integrating primary human tissue samples into target selection and discovery research to generate data that is more clinically relevant and individualized earlier in the drug discovery process, increasing the probability of success.

Product: Medable Decentralized Clinical Trials Platform

Company: Medable

Therapeutic Area & Indication:
Tools for managing trials remotely, including digital home screening of patients, teleconsent and televisit services, and external clinical outcomes assessments.

About the Product:
Medable directly improves the global human condition by helping solve one of the largest disparities in healthcare: participant access to clinical trials. 

Product: MammoScreen®

Company: Therapixel

Therapeutic Area & Indication: AI-based software to support radiologists interpret mammograms for early detection of breast cancer.

About the Product:
MammoScreen® is a software that helps radiologists with the interpretation of screening mammograms. With MammoScreen, even experienced radiologists improve their performance, feel more confident in their decision, and find more cancers. MammoScreen is an AI-based proficiency tool working alongside radiologists. Its uniquely actionable MammoScreen Score™ allows them to quickly confirm what they suspect and detect what they have missed. They can concentrate their energy on the questionable cases that require further scrutiny, while reassuring women quicker otherwise. Winner of the DREAM Digital Mammography Challenge, the largest competition ever organized in AI for breast imaging. Subscription-based and vendor-neutral, easily fits into existing infrastructure providing non-intrusive zero-click workflow.

Product: ContaCT

Company: Viz.ai

Therapeutic Area & Indication: AI algorithm to precision analyze images for large vessel occlusive stroke allowing for rapid, time-sensitive patient diagnosis and treatment.

About the Product:
Viz.ai pioneered the use of AI algorithms and machine learning to increase the speed of diagnosis and care for a variety of diseases across health systems. The Viz Platform is an intelligent care coordination solution that unifies synchronized care collaboration, high fidelity mobile image viewing, automated workflows and improved visibility at decision-making moments. Viz.ai’s comprehensive AI platform is clinically proven to save time and improve patient outcomes and access to care and is used in more than 1,200 hospitals. Viz.ai’s life science portfolio expands the power of the AI-powered Platform to pharmaceutical and medical device companies who are leaning into digital transformation to bring life-saving therapies to market more efficiently.

Harpreet is currently VP Primary Care at Huma and a NHS primary care doctor. Harpreet also sits on the board of Health Education England, a $5.5bn organisation training and developing 160,000 staff across the NHS, where his focus is on developing digital and data science skills and training for the workforce and Wesleyan, a financial services mutual.

Harpreet was formerly the first Associate Chief Clinical Information Officer (CCIO) at NHS England and prior to this Senior Fellow to the CEO of NHS England, where he advised senior NHS policymakers on NHS innovation and technology policy. As the Associate CCIO, Harpreet was involved in and developing and implementing NHS England's digital health and data strategy, including co-founding and leading on the NHS Digital Academy, one of the key initiatives from the strategy. Harpreet also has international experience of working in the US where he co-founded a digital health startup in Boston and worked at Brigham and Women's Hospital.

Harpreet trained as a clinical doctor at King’s College London and Imperial College Business School and completed a Masters in Public Health (MPH) at Harvard University

Product: MouthLab Vital Signs Monitoring System

Company: Aidar Health, Inc.

Therapeutic Area & Indication: Breath and saliva-based biosensors to help support
effective interventions for respiratory, cardiovascular and oncology conditions.

About the Product:
Aidar's flagship product is the FDA-cleared and CE-Mark-approved, non-invasive, hand-held rapid health assessment device, MouthLab, which measures 10+ medical parameters in < 60secs. Aidar combined data from MouthLab, with connected software technology with innovative data science, to create the Aidar Kidney Index, an algorithm to identify multi-parametric changes in a person’s biomarkers that could predict health-related complications or decompensating events, such as one necessitating hospitalization. This index will enable early detection of deterioration and provide timely intervention to at-risk chronic kidney disease patients, thereby preventing hospitalization or morbidity events. MouthLab is like a ‘check engine’ light for humans.

Product: Butterfly iQ+

Company: Butterfly Network, Inc.

Therapeutic Area & Indication: Ultrasound on a Chip technology that makes standard medical imaging screens more accessible and affordable for patients.

About the Product:
Butterfly Network is a digital health company that reinvented ultrasound by replacing piezoelectric crystal sensors with a single silicon chip the size of a postage stamp. With Ultrasound-On-Chip™ technology, the Butterfly iQ+ makes medical imaging more accessible and affordable than ever before. Now, through this portable, handheld device – protected by a robust intellectual property portfolio and empowered by proprietary software and Artificial Intelligence – Butterfly is driving a paradigm shift in the standard of care for all patients, worldwide, by enabling easier delivery of imaging information to improve accuracy, speed, cost efficiency, and excellence of care.

Product: JINKO

Company: Novadiscovery

Therapeutic Area & Indication: Clinical trial simulation software to beta-test trial designs on virtual patients prior to initiating trials with human subjects.

About the Product:
Jinkō® is a clinical trial simulation platform that allows clinical development teams to beta-test trial designs on virtual patients before running clinical trials on human subjects. Our platform and library of disease models give a unique competitive advantage to users to get insights needed to optimize trial protocols (dose, combination of treatments, regiment, inclusion/exclusion criteria - best responders) by testing an unlimited number of designs on an unlimited number of virtual patients. In doing so, our users maximize the odds of a successful trial. Jinkō has been applied to different indications, including Non-Small cell lung cancer (NSCLC), Hepatitis B (HBV), Atopic Dermatitis (AD) and many more.

Product: Patientory

Company: Patientory, Inc.

Therapeutic Area & Indication: App to democratize and provide actionable insights from health data in a way that incentivizes individuals to control their own personal health outcomes.

About the Product:
Patientory transform healthcare data access by providing a secure decentralized marketplace for patients to share real time clinical information with healthcare stakeholders improving the time and costs for clinical research studies and trial recruitment.